We also tested the ability for cell surface markers and CRP to predict MOF and sepsis within the complicated patient groups alone, which is likely to represent a realistic target patient group in whom clinicians would want to assess the risk of sepsis/MOF (e.g., SIRS vs. sepsis in the ICU). This evidence concerns the gene CRP and systemic inflammatory response syndrome.